Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Coherus Biosciences, Inc. operates as a biopharmaceutical company. The Company develops biosimilar therapeutics to aid patients.
Website: coherus.com



Growth: Good revenue growth rate 104.4%, there is acceleration compared to average historical growth rates -12.1%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -77.5%. On average the margin is improving steadily. Gross margin is low, +6.4%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 40% of quarters (showing a gain of -$0.14 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -41.6% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 50.3% higher than minimum and 87.4% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -1.2x by EV / Sales multiple

Key Financials (Download financials)

Ticker: CHRS
Share price, USD:  (-1.2%)2.39
year average price 3.93  


year start price 6.84 2023-03-31

max close price 8.30 2023-04-21

min close price 1.59 2023-11-10

current price 2.39 2024-03-29
Common stocks: 77 423 000

Dividend Yield:  0.0%
Last revenue growth (y/y):  104.4%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  -12.1%
Historical growth of EBITDA:  -60.5%
EV / Sales: 2.1x
Margin (EBITDA LTM / Revenue): -77.5%
Fundamental value created in LTM:
Market Cap ($m): 185
Net Debt ($m): 356
EV (Enterprise Value): 541
Price to Book: -1.0x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-03-20Seeking Alpha

Coherus Biosciences: Dumping One Drug But Showing Promise With Another

2024-03-14The Motley Fool

Why Coherus Biosciences Stock Tumbled on Thursday

2024-03-13Seeking Alpha

Coherus BioSciences, Inc. (CHRS) Q4 2023 Earnings Call Transcript

2024-02-06The Motley Fool

Why Coherus BioSciences Stock Jumped Today

2024-01-23The Motley Fool

Why Coherus BioSciences Stock Is Sinking Today

2024-01-22The Motley Fool

Why Coherus Biosciences Popped Today

2024-01-22InvestorPlace

Why Is Coherus BioSciences (CHRS) Stock Up 17% Today?

2023-12-28The Motley Fool

Why Coherus BioSciences Stock Jumped Today

2023-12-28Zacks Investment Research

Coherus (CHRS) Stock Rallies on FDA Nod for Udenyca Onbody

2023-12-27Proactive Investors

Coherus BioSciences shares take off on FDA approval of drug delivery device
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol CHRS CHRS CHRS CHRS CHRS CHRS
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-03-15 2023-11-06 2023-08-02 2023-05-08 2023-03-06 2022-11-08
acceptedDate 2024-03-15 17:13:21 2023-11-06 16:35:59 2023-08-02 16:11:32 2023-05-08 16:20:06 2023-03-06 16:16:08 2022-11-08 16:03:00
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
revenue 92M 75M 59M 32M 45M 45M
costOfRevenue 86M 33M 25M 17M 14M 35M
grossProfit 6M 42M 34M 16M 31M 10M
grossProfitRatio 0.064 0.561 0.577 0.480 0.687 0.224
researchAndDevelopmentExpenses 25M 26M 23M 34M 29M 46M
generalAndAdministrativeExpenses 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 49M 48M 45M 49M 54M 45M
otherExpenses -129 000 2M 2M 2M 2M 0
operatingExpenses 74M 74M 68M 83M 83M 91M
costAndExpenses 160M 107M 93M 100M 97M 126M
interestIncome 0 10M 10M 0 0 0
interestExpense 11M -10M 10M 10M 9M 8M
depreciationAndAmortization 1M 899 000 880 000 2M 2M 2M
ebitda -67M -32M -32M -66M -49M -78M
ebitdaratio -0.735 -0.429 -0.546 -2.035 -1.091 -1.720
operatingIncome -68M -32M -35M -68M -51M -80M
operatingIncomeRatio -0.747 -0.429 -0.588 -2.089 -1.135 -1.771
totalOtherIncomeExpensesNet -11M -8M 2M -8M -7M -6M
incomeBeforeTax -80M -40M -43M -76M -59M -87M
incomeBeforeTaxRatio -0.870 -0.537 -0.730 -2.335 -1.298 -1.908
incomeTaxExpense 0 -380 000 12M -949 000 7M 6M
netIncome -80M -40M -43M -75M -66M -93M
netIncomeRatio -0.870 -0.532 -0.730 -2.305 -1.461 -2.044
eps -0.710 -0.410 -0.490 -0.940 -0.850 -1.190
epsdiluted -0.710 -0.410 -0.490 -0.940 -0.850 -1.190
weightedAverageShsOut 111M 98M 87M 79M 78M 78M
weightedAverageShsOutDil 111M 98M 87M 79M 78M 78M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol CHRS CHRS CHRS CHRS CHRS CHRS
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-03-15 2023-11-06 2023-08-02 2023-05-08 2023-03-06 2022-11-08
acceptedDate 2024-03-15 17:13:21 2023-11-06 16:35:59 2023-08-02 16:11:32 2023-05-08 16:20:06 2023-03-06 16:16:08 2022-11-08 16:03:00
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 103M 80M 73M 16M 64M 287M
shortTermInvestments 15M 51M 72M 112M 128M 0
cashAndShortTermInvestments 118M 131M 145M 128M 192M 287M
netReceivables 261M 217M 141M 101M 110M 91M
inventory 63M 67M 64M 114M 115M 28M
otherCurrentAssets 35M 16M 18M 21M 23M 43M
totalCurrentAssets 476M 444M 385M 344M 417M 448M
propertyPlantEquipmentNet 11M 6M 7M 8M 9M 10M
goodwill 943 000 943 000 0 0 0 0
intangibleAssets 71M 46M 6M 0 0 0
goodwillAndIntangibleAssets 72M 47M 6M 6M 6M 6M
longTermInvestments 452 000 0 0 0 0 0
taxAssets 71M 0 0 0 0 0
otherNonCurrentAssets 87 000 87M 71M 45M 49M 87M
totalNonCurrentAssets 154M 139M 84M 58M 64M 103M
otherAssets 0 0 0 0 0 0
totalAssets 630M 584M 470M 402M 481M 551M
accountPayables 35M 37M 29M 23M 12M 10M
shortTermDebt 2M 4M 4M 4M 4M 4M
taxPayables 0 0 0 0 0 0
deferredRevenue 0 -4M -4M 0 0 0
otherCurrentLiabilities 294M 203M 140M 28M 39M 157M
totalCurrentLiabilities 332M 240M 169M 56M 54M 171M
longTermDebt 473M 474M 475M 472M 471M 477M
deferredRevenueNonCurrent 5M 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 1M 0 0 0 0 0
otherNonCurrentLiabilities 11M 4M 102 000 72M 93M 463M
totalNonCurrentLiabilities 491M 478M 475M 543M 564M 477M
otherLiabilities 0 0 0 0 0 0
capitalLeaseObligations 5M 6M 7M 8M 9M 10M
totalLiabilities 823M 717M 644M 599M 618M 648M
preferredStock 0 0 0 0 0 0
commonStock 11 000 11 000 9000.000 8000.000 8000.000 7000.000
retainedEarnings -1 580M -1 500M -1 460M -1 417M -1 342M -1 283M
accumulatedOtherComprehensiveIncomeLoss -248 000 -265 000 -297 000 -278 000 -249 000 -270 000
othertotalStockholdersEquity 1 386M 1 367M 1 286M 1 221M 1 204M 1 186M
totalStockholdersEquity -193M -134M -175M -197M -137M -97M
totalEquity -193M -134M -175M -197M -137M -97M
totalLiabilitiesAndStockholdersEquity 630M 584M 470M 402M 481M 551M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 630M 584M 470M 402M 481M 551M
totalInvestments 15M 51M 72M 112M 128M 0
totalDebt 481M 479M 479M 472M 471M 481M
netDebt 378M 398M 406M 455M 408M 194M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol CHRS CHRS CHRS CHRS CHRS CHRS
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-03-15 2023-11-06 2023-08-02 2023-05-08 2023-03-06 2022-11-08
acceptedDate 2024-03-15 17:13:21 2023-11-06 16:35:59 2023-08-02 16:11:32 2023-05-08 16:20:06 2023-03-06 16:16:08 2022-11-08 16:03:00
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
netIncome -80M -40M -43M -76M -59M -87M
depreciationAndAmortization 1M 899 000 880 000 949 000 1M 995 000
deferredIncomeTax -70M 874 000 -1M 0 0 0
stockBasedCompensation 11M 10M 10M 12M 12M 12M
changeInWorkingCapital 6M -28M -6M -9M -55M 9M
accountsReceivables -44M -75M -40M 9M -19M 25M
inventory -12M -19M -13M -3M -10M -23M
accountsPayables -785 000 7M 6M 12M 2M -8M
otherWorkingCapital 63M 60M 41M -27M -28M 15M
otherNonCashItems 118M 1M 468 000 3M 754 000 28M
netCashProvidedByOperatingActivities -13M -54M -39M -69M -100M -37M
investmentsInPropertyPlantAndEquipment -34 000 0 -100 000 -152 000 -87 000 -457 000
acquisitionsNet 76 000 151 000 440 000 0 0 0
purchasesOfInvestments 0 0 -20M 0 -127M 0
salesMaturitiesOfInvestments 36M 43M 61M 18M 0 0
otherInvestingActivites -1M 7M 0 178 000 -2M 0
netCashUsedForInvestingActivites 35M 51M 41M 18M -130M -457 000
debtRepayment 0 0 0 0 -191M 0
commonStockIssued 891 000 11M 54M 7M 6M 0
commonStockRepurchased 0 -175 000 -305 000 0 0 0
dividendsPaid 0 0 0 0 0 0
otherFinancingActivites -525 000 -157 000 1M -3M 191M 49M
netCashUsedProvidedByFinancingActivities 366 000 11M 54M 4M 7M 49M
effectOfForexChangesOnCash -452 000 3M 0 0 0 0
netChangeInCash 22M 7M 57M -47M -223M 11M
cashAtEndOfPeriod 103M 81M 73M 17M 64M 287M
cashAtBeginningOfPeriod 81M 73M 17M 64M 287M 276M
operatingCashFlow -13M -54M -39M -69M -100M -37M
capitalExpenditure -34 000 0 -100 000 -152 000 -87 000 -457 000
freeCashFlow -13M -54M -39M -69M -100M -38M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

2023 q4
2024-03-13 ET (fiscal 2023 q4)
2023 q3
2023-11-07 ET (fiscal 2023 q3)
2023 q2
2023-08-02 ET (fiscal 2023 q2)
2023 q1
2023-05-08 ET (fiscal 2023 q1)
2022 q4
2023-03-06 ET (fiscal 2022 q4)
2022 q3
2022-11-08 ET (fiscal 2022 q3)
2022 q2
2022-08-07 ET (fiscal 2022 q2)
2022 q1
2022-05-05 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-03-13 20:01 ET
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
2024-03-05 21:01 ET
Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024
2024-03-04 06:00 ET
Coherus Completes Divestiture of Ophthalmology Franchise
2024-02-23 22:33 ET
Coherus BioSciences Announces New Employment Inducement Grants
2024-02-21 13:30 ET
Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
2024-02-05 13:00 ET
Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP
2024-01-22 06:15 ET
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal
2024-01-18 21:05 ET
Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium
2024-01-03 14:00 ET
Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2024-01-02 13:29 ET
Coherus Announces U.S. Launch of LOQTORZI™
2023-12-26 21:01 ET
Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
2023-12-22 22:00 ET
Coherus BioSciences Announces New Employment Inducement Grants
2023-12-11 13:30 ET
Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI™ (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx
2023-12-07 22:55 ET
Coherus BioSciences Announces CFO Transition Plans
2023-12-06 09:00 ET
Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress
2023-11-28 16:16 ET
Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI™ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Ass...
2023-11-06 21:07 ET
Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights
2023-11-03 12:30 ET
Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC)
2023-11-03 00:00 ET
Coherus BioSciences to Participate at Upcoming November Investor Conferences
2023-10-30 22:00 ET
Coherus BioSciences to Report Third Quarter 2023 Financial Results on November 6, 2023
2023-10-27 19:07 ET
Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI™ (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
2023-10-24 23:41 ET
Coherus BioSciences Announces New Employment Inducement Grants
2023-10-14 16:30 ET
Coherus Announces Toripalimab Data at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
2023-10-05 12:30 ET
Coherus Announces Resubmission of Biologics License Application (BLA) Supplement for UDENYCA® ONBODY™
2023-10-04 12:30 ET
CIMERLI® (ranibizumab-eqrn) Sales Exceed 100,000 Doses in First Year of Launch
2023-10-02 13:00 ET
Coherus Applauds Congressional Designation of September 30th as Rare Cancer Day
2023-09-27 13:10 ET
Coherus Announces Three Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
2023-09-25 12:30 ET
FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY™ Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus Also Announces Completion of Toripalimab FDA Inspections
2023-09-23 01:00 ET
Coherus BioSciences Announces New Employment Inducement Grants
2023-09-08 13:05 ET
Coherus Completes Surface Oncology Acquisition
2023-09-01 20:01 ET
Coherus BioSciences to Participate at Upcoming September Investor Conferences
2023-08-31 20:01 ET
Surface Oncology Announces ISS and Glass Lewis Both Recommend Stockholders Vote “FOR” the Proposed Merger with Coherus BioSciences
2023-08-22 21:35 ET
Coherus BioSciences Announces New Employment Inducement Grants
2023-08-02 20:01 ET
Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights
2023-07-26 20:05 ET
Coherus BioSciences to Report Second Quarter 2023 Financial Results on August 02, 2023
2023-07-21 21:30 ET
Coherus BioSciences Announces New Employment Inducement Grants
2023-07-20 20:04 ET
Coherus BioSciences Appoints Dr. Michael Ryan to its Board of Directors
2023-07-13 12:30 ET
Coherus and Superior Biologics Announce National Distribution Agreement for YUSIMRY™
2023-07-03 12:30 ET
Coherus Launches YUSIMRY™, a Biosimilar of Humira®, at $995 per Carton in U.S.
2023-06-27 01:08 ET
Coherus BioSciences Announces New Employment Inducement Grants
2023-06-16 11:01 ET
Coherus to Acquire Surface Oncology
2023-06-05 21:30 ET
Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma
2023-06-01 12:33 ET
Mark Cuban Cost Plus Drug Company joins forces with Coherus to make YUSIMRY™, a HUMIRA® biosimilar, available to patients
2023-06-01 12:30 ET
Coherus Announces Industry-Wide Lowest List Price for Adalimumab Biosimilar YUSIMRY™ (adalimumab-aqvh) Launching in July 2023
2023-05-22 12:30 ET
Coherus Announces U.S. Launch of UDENYCA® Autoinjector
2023-05-16 10:50 ET
Coherus Prices Public Offering of Common Stock
2023-05-15 20:01 ET
Coherus Announces Proposed Public Offering of Common Stock
2023-05-08 20:05 ET
Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights
2023-05-04 20:30 ET
Coherus BioSciences to Present at Upcoming Investor Conferences in May
2023-05-01 20:07 ET
Coherus BioSciences to Report First Quarter 2023 Financial Results on May 8, 2023
2023-04-27 12:05 ET
Coherus and Junshi Biosciences Announce Toripalimab Studies to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
2023-03-06 21:01 ET
Coherus BioSciences Reports Fourth Quarter and Full Year 2022 Results
2023-03-06 13:00 ET
FDA Approves UDENYCA® Autoinjector
2023-03-01 13:25 ET
Coherus BioSciences to Present at Upcoming Investor Conferences in March
2023-02-28 13:25 ET
Coherus BioSciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
2023-02-15 13:25 ET
Coherus and Junshi Biosciences Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma
2023-02-13 13:25 ET
Coherus Granted Permanent, Product-Specific Q-Code for CIMERLI® (ranibizumab-eqrn) from the Centers for Medicare and Medicaid Services
2023-02-03 22:30 ET
Coherus BioSciences Announces New Employment Inducement Grants
2023-01-09 13:20 ET
Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea® Biosimilar FYB203 from Klinge Biopharma
2023-01-04 12:01 ET
Coherus BioSciences Management to Present at the 41st Annual J.P. Morgan Healthcare Conference
2022-12-25 13:16 ET
Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
2022-12-24 05:01 ET
Coherus and Junshi Biosciences Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
2022-11-08 21:01 ET
Coherus BioSciences Reports Third Quarter 2022 Results and Provides Business Update
2022-11-01 11:30 ET
Coherus BioSciences to Report Third Quarter 2022 Financial Results on November 8th, 2022
2022-10-12 11:30 ET
Coherus and Junshi Biosciences Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, in the Journal of Clinical...
2022-09-19 11:30 ET
Coherus to Launch CIMERLI™ (ranibizumab-eqrn) in the United States on October 3, 2022
2022-09-12 12:30 ET
Coherus BioSciences Management to Present at H.C. Wainwright 24th Annual Global Investment Conference
2022-08-30 00:49 ET
Coherus BioSciences Announces New Employment Inducement Grants
2022-08-04 20:01 ET
Coherus BioSciences Reports Second Quarter 2022 Results and Provides Business Update
2022-08-02 23:15 ET
FDA Approves Coherus’ CIMERLI™ (ranibizumab-eqrn) as the First and Only Interchangeable Biosimilar to Lucentis® for All Five Indications, with 12 Months of Interchangeability Exclusivity
2022-08-02 03:15 ET
Coherus BioSciences Announces New Employment Inducement Grants
2022-07-28 20:01 ET
Coherus BioSciences to Report Second Quarter 2022 Financial Results on August 4th, 2022
2022-07-06 12:00 ET
Coherus and Junshi Biosciences Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
2022-06-22 20:30 ET
Coherus BioSciences Announces New Employment Inducement Grants
2022-05-11 22:00 ET
Coherus BioSciences Appoints Dr. Jill O’Donnell-Tormey to its Board of Directors
2022-05-10 12:45 ET
Coherus BioSciences Management to Present at Upcoming Investor Conferences
2022-05-05 20:01 ET
Coherus BioSciences Reports First Quarter 2022 Results
2022-05-05 12:31 ET
Coherus BioSciences Appoints Charlie Newton to Board of Directors
2022-05-04 01:44 ET
Coherus BioSciences Announces New Employment Inducement Grants
2022-05-02 11:00 ET
Coherus and Junshi Biosciences Receive Complete Response Letter from U.S. FDA for Toripalimab BLA
2022-04-29 12:45 ET
Coherus BioSciences to Report First Quarter 2022 Financial Results on May 5th, 2022
2022-04-14 12:30 ET
Coherus and Junshi Biosciences Announce PD-1 Inhibitor Toripalimab Granted Orphan Drug Designation for Small Cell Lung Cancer in the United States
2022-04-08 17:10 ET
Coherus and Junshi Biosciences Present Results of Phase 3 Study of Toripalimab in First Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma at 2022 AACR Annual Meeting
2022-04-05 20:30 ET
Coherus BioSciences Announces New Employment Inducement Grants
2022-03-29 13:15 ET
Coherus Highlights Anticipated New Product Launches and Immuno-oncology Growth Strategy at Analyst Day Event
2022-03-22 20:30 ET
Coherus BioSciences to Highlight New Product Pipeline, Cancer Immunotherapy Development Plans at March 29, 2022 Analyst Day Event
2022-03-15 12:00 ET
Coherus BioSciences Appoints Rosh Dias, MD, MRCP, Chief Medical Officer
2022-03-15 11:30 ET
Junshi Biosciences and Coherus Announce Presentation of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, at March ASCO Plenary Series
2022-03-04 21:05 ET
Coherus Management to Present at Upcoming Investor Conferences
2022-03-04 13:00 ET
Coherus and Junshi Biosciences Announce Positive Results from Phase 3 Esophageal Cancer Study of Toripalimab Published in Cancer Cell
2022-02-17 21:01 ET
Coherus BioSciences Reports Fourth Quarter and Full Year 2021 Results
2022-02-15 21:30 ET
Coherus Names Paul Reider Chief Commercial Officer
2022-02-14 13:30 ET
Coherus BioSciences Announces New Employment Inducement Grants
2022-02-11 13:30 ET
Coherus BioSciences to Report Fourth Quarter and Full Year 2021 Financial Results on February 17th, 2022
2022-02-07 13:30 ET
Coherus BioSciences Appoints Health Care Payer Expert Lee N. Newcomer, M.D., to Board of Directors
2022-01-10 12:30 ET
Coherus and Junshi Biosciences Expand Immuno-Oncology Collaboration to Include TIGIT-Targeted Antibody
2022-01-07 13:30 ET
Coherus BioSciences Secures Credit Financing with Pharmakon Advisors
2022-01-04 13:32 ET
Coherus BioSciences Management to Present at the 40th Annual J.P. Morgan Healthcare Conference
2021-12-20 12:59 ET
Coherus Announces U.S. FDA Approval of YUSIMRY™ (adalimumab-aqvh)
2021-12-17 14:09 ET
Coherus BioSciences Appoints Theresa LaVallee, Ph.D., Chief Development Officer
2021-12-16 21:30 ET
Coherus BioSciences Announces New Employment Inducement Grants
2021-12-13 12:00 ET
Junshi Biosciences and Coherus Announce Positive Interim Overall Survival Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
2021-11-15 13:30 ET
Coherus and Junshi Biosciences Announce Toripalimab Granted Orphan Drug Designation in the United States for Esophageal Cancer
2021-11-10 21:15 ET
Coherus BioSciences Announces New Employment Inducement Grants
2021-11-08 21:01 ET
Coherus BioSciences Reports Third Quarter 2021 Results
2021-11-05 12:30 ET
Coherus BioSciences Announces CMS Has Extended Enhanced Medicare Reimbursement for UDENYCA® in the 340B Hospital Setting Through Year-End 2022
2021-11-01 11:30 ET
Junshi Biosciences and Coherus Announce FDA Acceptance of BLA Filing for Toripalimab for Treatment of Nasopharyngeal Carcinoma
2021-11-01 11:30 ET
Coherus and Junshi Biosciences Announce FDA Acceptance of BLA Filing for Toripalimab for Treatment of Nasopharyngeal Carcinoma
2021-10-29 20:11 ET
Coherus BioSciences to Report Third Quarter 2021 Financial Results on November 8th
2021-10-11 12:30 ET
Coherus BioSciences Mourns the Passing of Board Member Alan C. Mendelson
2021-10-05 12:00 ET
Coherus Announces Positive Results of UDENYCA® On-Body Injector Clinical Trial
2021-10-04 12:00 ET
Positive Results of Clinical Trial Comparing Coherus’ Ranibizumab Biosimilar Candidate CHS-201 to Reference Product Lucentis® (Ranibizumab) in the Treatment of Neovascular (Wet) Age-Related Macular Degeneration (nAMD) Presented at Retina Society Annua...
2021-10-01 17:09 ET
Coherus Announces BLA Filing for Lucentis® (ranibizumab) Biosimilar Candidate Accepted by FDA for Review
2021-09-29 20:30 ET
Coherus BioSciences Mourns the Passing of Board Member Dr. Samuel Nussbaum
2021-09-24 20:15 ET
Coherus BioSciences Announces New Employment Inducement Grants
2021-09-16 22:28 ET
Coherus and Junshi Biosciences to Present Positive Progression Free Survival and Overall Survival Results from JUPITER-06, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Esophageal...
2021-09-15 12:30 ET
Coherus and Junshi Biosciences Announce Results from Phase 3 Study of Toripalimab Published in September Issue of Nature Medicine
2021-09-14 00:35 ET
Positive Interim Results of CHOICE-01 Study Evaluating Coherus' and Junshi Biosciences’ Toripalimab for First Line Treatment of Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer
2021-09-10 12:45 ET
Coherus Management to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
2021-09-08 12:30 ET
Coherus BioSciences Announces Upcoming Medical Conference Presentations
2021-09-01 12:01 ET
Coherus and Junshi Biosciences Announce Completion of Rolling BLA Submission to U.S. FDA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
2021-08-27 20:15 ET
Coherus BioSciences Announces New Employment Inducement Grants
2021-08-19 01:09 ET
Junshi and Coherus Biosciences Announce Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
2021-08-18 22:41 ET
Coherus and Junshi Biosciences Announce Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
2021-08-12 12:01 ET
Junshi Biosciences and Coherus Announce U.S. FDA Breakthrough Therapy Designation Granted for Toripalimab for 1st Line Treatment of Nasopharyngeal Carcinoma
2021-08-12 12:01 ET
Junshi Biosciences and Coherus Announce U.S. FDA Breakthrough Therapy Designation Granted for Toripalimab for 1st Line Treatment of Nasopharyngeal Carcinoma
2021-08-05 20:01 ET
Coherus BioSciences Reports Second Quarter 2021 Financial Results and Immuno-oncology and Biosimilar Pipeline Progress
2021-07-26 20:31 ET
Coherus BioSciences to Report Second Quarter 2021 Financial Results on August 5th
2021-07-21 13:15 ET
Coherus BioSciences Names Physician-Scientist Ildiko Csiki, M.D., Ph.D., Chair of its Scientific Advisory Board
2021-07-13 00:29 ET
Coherus BioSciences Announces New Employment Inducement Grants
2021-06-04 20:01 ET
Coherus and Junshi Biosciences to Host Virtual Investor Event to Discuss Toripalimab and ASCO 2021 Highlights
2021-06-04 00:45 ET
Coherus and Junshi Biosciences Announce Toripalimab in Combination with Chemotherapy Met Primary Progression Free Survival (PFS) Endpoint as First Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
2021-06-03 21:00 ET
Coherus and Junshi Biosciences Announce Toripalimab in Combination with Chemotherapy Met Primary Progression Free Survival (PFS) Endpoint as First Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
2021-05-07 20:01 ET
Coherus BioSciences to Present at the Bank of America Health Care Conference
2021-05-06 20:01 ET
Coherus BioSciences Reports First Quarter 2021 Financial Results and Immuno-oncology and Biosimilar Pipeline Progress
2021-04-30 20:15 ET
Coherus BioSciences Announces New Employment Inducement Grants
2021-04-30 12:15 ET
Coherus BioSciences to Report First Quarter 2021 Financial Results on May 6th
2021-04-29 11:30 ET
Junshi Biosciences and Coherus Announce Toripalimab First-Line Nasopharyngeal Carcinoma Clinical Data to be Showcased in Plenary Session at 2021 ASCO Annual Meeting
2021-04-23 12:00 ET
Coherus Announces Toripalimab Achieved Primary Endpoints of Progression Free Survival and Overall Survival in Interim Analysis of Phase 3 Clinical Trial in First-Line Esophageal Squamous Cell Carcinoma
2021-04-20 12:00 ET
Coherus Announces Closing of Sale of Common Stock to Immuno-Oncology Partner Junshi Biosciences
2021-03-03 11:45 ET
Junshi Biosciences and Coherus BioSciences Announce Initiation of Rolling Submission of BLA for Toripalimab to the U.S. FDA for the Treatment of Nasopharyngeal Carcinoma
2021-02-25 13:45 ET
Coherus Management to Present at Upcoming Investor Conferences
2021-02-24 21:01 ET
Coherus BioSciences Reports Fourth Quarter and Full Year 2020 Financial Results
2021-02-18 13:30 ET
Coherus BioSciences to Report Fourth Quarter and Full Year 2020 Financial Results on February 24th
2021-02-17 12:30 ET
Coherus BLA Filing for Adalimumab Biosimilar Candidate Accepted by FDA for Review
2021-02-16 13:00 ET
Coherus Announces CFO Transition Plans
2021-02-02 13:30 ET
Coherus BioSciences to Receive $50 million Strategic Investment from Immuno-Oncology Partner Junshi Biosciences
2021-02-02 13:30 ET
Coherus BioSciences to Receive $50 million Strategic Investment from Immuno-Oncology Partner Junshi Biosciences
2021-02-01 12:53 ET
Junshi Biosciences and Coherus BioSciences Announce Collaboration to Co-Develop Anti-PD-1 Antibody, Toripalimab, in U.S. and Canada
2021-02-01 10:30 ET
Coherus BioSciences to expand late-stage pipeline to immuno-oncology with in-license of Junshi Biosciences’ PD-1, toripalimab, in United States and Canada
2021-01-22 21:01 ET
Coherus BioSciences Announces New Employment Inducement Grants
2021-01-07 21:01 ET
Coherus BioSciences Appoints Alan Mendelson and Mark Stolper to Board of Directors
2021-01-05 21:01 ET
Coherus BioSciences Management to Present at the 39th Annual J.P. Morgan Healthcare Conference
2020-12-21 21:02 ET
Coherus BioSciences Announces New Employment Inducement Grants
2020-11-20 21:01 ET
Coherus BioSciences Announces New Employment Inducement Grants
2020-11-05 21:02 ET
Coherus BioSciences Reports Third Quarter 2020 Financial Results
2020-10-22 20:15 ET
Coherus BioSciences to Report Third Quarter Financial Results on November 5th
2020-10-16 13:30 ET
Coherus BioSciences Announces New Employment Inducement Grants
2020-09-18 15:02 ET
Coherus BioSciences Announces New Employment Inducement Grants
2020-08-21 13:30 ET
Coherus BioSciences Announces New Employment Inducement Grants
2020-08-06 20:02 ET
Coherus BioSciences Reports Second Quarter 2020 Financial Results
2020-08-03 20:48 ET
Coherus BioSciences Appoints Kimberly Tzoumakas, J.D. to Board of Directors
2020-07-17 13:30 ET
Coherus BioSciences Announces New Employment Inducement Grants
2020-07-16 13:30 ET
Coherus BioSciences to Report Second Quarter Financial Results on August 6th
2020-06-19 13:30 ET
Coherus BioSciences Announces New Employment Inducement Grants
2020-05-07 20:08 ET
Coherus BioSciences Reports First Quarter 2020 Financial Results
2020-05-04 13:30 ET
Coherus BioSciences Management to Present at BofA Securities 2020 Health Care Conference
2020-04-22 13:30 ET
Coherus BioSciences to Report First Quarter Financial Results on May 7th
2020-04-15 04:05 ET
Coherus BioSciences Prices $200.0 Million Convertible Senior Subordinated Notes Offering
2020-04-14 11:52 ET
Coherus BioSciences Announces Proposed Convertible Senior Subordinated Notes Offering
2020-04-13 13:22 ET
Coherus BioSciences Provides First Quarter 2020 Financial Update and Fiscal Year 2020 COVID-19 Impact Insights
2020-03-20 13:30 ET
Coherus BioSciences Announces New Employment Inducement Grants
2020-03-05 21:09 ET
Coherus BioSciences Management to Present at Barclays Global Healthcare Conference 2020
2020-03-05 12:00 ET
United States Manufactured UDENYCA® (pegfilgrastim-cbqv) Well Positioned to Meet Market Demand
2020-02-27 21:01 ET
Coherus BioSciences Reports Fourth Quarter and Full Year 2019 Financial Results
2020-02-26 14:30 ET
Coherus BioSciences Management to Present at the 40th Annual Cowen Healthcare Conference
2020-02-20 16:19 ET
Coherus BioSciences Announces New Employment Inducement Grants
2020-02-06 14:34 ET
Coherus BioSciences to Report Fourth Quarter and Full Year Financial Results on February 27th
2020-01-13 13:30 ET
Coherus Acquires Commercial Rights for Avastin® Biosimilar in the United States
2020-01-03 14:30 ET
Coherus BioSciences Management to Present at the 38th Annual J.P. Morgan Healthcare Conference
2019-11-12 14:30 ET
Coherus BioSciences Management to Present at Two Upcoming Investor Healthcare Conferences
2019-11-08 14:30 ET
Coherus BioSciences Announces New Employment Inducement Grants
2019-11-06 21:01 ET
Coherus Acquires Commercial Rights for Leading Lucentis Biosimilar in the United States
2019-11-06 21:01 ET
Coherus BioSciences Reports Corporate Highlights and Third Quarter 2019 Financial Results
2019-10-18 13:30 ET
Coherus BioSciences Announces New Employment Inducement Grants
2019-10-15 13:30 ET
Coherus BioSciences to Report Third Quarter Financial Results on November 6th
2019-09-20 13:30 ET
Coherus BioSciences Announces New Employment Inducement Grants
2019-04-19 13:30 ET
Coherus BioSciences Announces New Employment Inducement Grants
2019-04-08 13:31 ET
Thinking about buying stock in Aurora Cannabis Inc., Chesapeake Energy Corp., Coherus Biosciences Inc., Snap Inc., or Vital Therapies Inc.
2019-04-05 20:00 ET
Coherus BioSciences Announces Unaudited First Quarter 2019 UDENYCA™ Net Sales
2019-04-05 12:30 ET
Coherus BioSciences to Report First Quarter Financial Results on May 9th
2019-03-28 13:30 ET
Coherus BioSciences Management to Present at H.C. Wainwright & Co. Global Life Sciences Conference
2019-03-22 13:30 ET
Coherus BioSciences Announces New Employment Inducement Grants
2019-03-08 12:00 ET
Oncolytics Biotech (R) Announces 2018 Year-End Results and Operational Highlights

SEC forms

Show financial reports only

SEC form 10
2024-03-15 00:00 ET
Coherus Biosciences published news for 2023 q4
SEC form 8
2024-03-13 16:16 ET
Coherus Biosciences published news for 2023 q4
SEC form 8
2024-03-13 16:16 ET
Coherus Biosciences reported for 2023 q4
SEC form 8
2024-01-10 00:00 ET
Coherus Biosciences published news for 2023 q4
SEC form 8
2024-01-10 00:00 ET
Coherus Biosciences published news for 2023 q4
SEC form 10
2023-11-06 16:35 ET
Coherus Biosciences reported for 2023 q3
SEC form 8
2023-11-06 16:31 ET
Coherus Biosciences published news for 2023 q3
SEC form 10
2023-11-06 00:00 ET
Coherus Biosciences published news for 2023 q3
SEC form 10
2023-08-02 16:11 ET
Coherus Biosciences reported for 2023 q2
SEC form 6
2023-08-02 16:05 ET
Coherus Biosciences published news for 2023 q2
SEC form 10
2023-08-02 00:00 ET
Coherus Biosciences published news for 2023 q2
SEC form 8
2023-08-02 00:00 ET
Coherus Biosciences published news for 2023 q2
SEC form 6
2023-07-20 17:10 ET
Coherus Biosciences published news for 2023 q2
SEC form 6
2023-07-20 17:01 ET
Coherus Biosciences published news for 2023 q2
SEC form 6
2023-06-16 07:06 ET
Coherus Biosciences published news for 2023 q1
SEC form 6
2023-06-15 06:05 ET
Coherus Biosciences published news for 2023 q1
SEC form 6
2023-06-09 17:01 ET
Coherus Biosciences published news for 2023 q1
SEC form 10
2023-05-08 00:00 ET
Coherus Biosciences published news for 2023 q1
SEC form 8
2023-05-08 00:00 ET
Coherus Biosciences published news for 2023 q1
SEC form 6
2023-03-28 18:48 ET
Coherus Biosciences published news for 2022 q4
SEC form 10
2023-03-06 16:16 ET
Coherus Biosciences published news for 2022 q4
SEC form 6
2023-03-06 16:11 ET
Coherus Biosciences published news for 2022 q4
SEC form 8
2023-03-06 00:00 ET
Coherus Biosciences reported for 2022 q4
SEC form 10
2023-03-06 00:00 ET
Coherus Biosciences reported for 2022 q4
SEC form 6
2023-01-12 19:42 ET
Coherus Biosciences published news for 2022 q4
SEC form 10
2022-11-08 16:03 ET
Coherus Biosciences published news for 2022 q3
SEC form 6
2022-11-08 16:01 ET
Coherus Biosciences published news for 2022 q3
SEC form 10
2022-11-08 00:00 ET
Coherus Biosciences reported for 2022 q3
SEC form 8
2022-11-08 00:00 ET
Coherus Biosciences reported for 2022 q3
SEC form 6
2022-10-06 16:06 ET
Coherus Biosciences published news for 2022 q3
SEC form 6
2022-09-15 16:34 ET
Coherus Biosciences published news for 2022 q2
SEC form 6
2022-09-09 17:36 ET
Coherus Biosciences published news for 2022 q2
SEC form 6
2022-09-09 16:46 ET
Coherus Biosciences published news for 2022 q2
SEC form 10
2022-08-04 16:35 ET
Coherus Biosciences published news for 2022 q2
SEC form 6
2022-08-04 16:25 ET
Coherus Biosciences published news for 2022 q2
SEC form 10
2022-08-04 00:00 ET
Coherus Biosciences reported for 2022 q2
SEC form 8
2022-08-04 00:00 ET
Coherus Biosciences reported for 2022 q2
SEC form 6
2022-05-20 17:18 ET
Coherus Biosciences published news for 2022 q1
SEC form 6
2022-05-20 16:50 ET
Coherus Biosciences published news for 2022 q1
SEC form 6
2022-05-13 16:44 ET
Coherus Biosciences published news for 2022 q1
SEC form 6
2022-05-10 16:58 ET
Coherus Biosciences published news for 2022 q1
SEC form 6
2022-05-06 18:47 ET
Coherus Biosciences published news for 2022 q1
SEC form 6
2022-05-06 18:43 ET
Coherus Biosciences published news for 2022 q1
SEC form 10
2022-05-05 16:38 ET
Coherus Biosciences published news for 2022 q1
SEC form 6
2022-05-05 16:28 ET
Coherus Biosciences published news for 2022 q1
SEC form 10
2022-05-05 00:00 ET
Coherus Biosciences reported for 2022 q1
SEC form 6
2022-04-04 16:05 ET
Coherus Biosciences published news for 2022 q1
SEC form 6
2022-04-01 16:16 ET
Coherus Biosciences published news for 2022 q1
SEC form 10
2022-02-23 17:29 ET
Coherus Biosciences published news for 2021 q4
SEC form 10
2022-02-23 00:00 ET
Coherus Biosciences published news for 2021 q4
SEC form 6
2022-02-17 16:39 ET
Coherus Biosciences published news for 2021 q4
SEC form 8
2022-02-17 00:00 ET
Coherus Biosciences published news for 2021 q4
SEC form 6
2022-02-07 17:17 ET
Coherus Biosciences published news for 2021 q4
SEC form 6
2022-02-04 20:19 ET
Coherus Biosciences published news for 2021 q4
SEC form 6
2022-01-13 16:39 ET
Coherus Biosciences published news for 2021 q4
SEC form 6
2022-01-07 08:36 ET
Coherus Biosciences published news for 2021 q4
SEC form 6
2021-12-03 17:28 ET
Coherus Biosciences published news for 2021 q3
SEC form 10
2021-11-08 16:11 ET
Coherus Biosciences published news for 2021 q3
SEC form 6
2021-11-08 16:06 ET
Coherus Biosciences published news for 2021 q3
SEC form 8
2021-11-08 00:00 ET
Coherus Biosciences published news for 2021 q3
SEC form 10
2021-11-08 00:00 ET
Coherus Biosciences published news for 2021 q3
SEC form 6
2021-10-13 17:01 ET
Coherus Biosciences published news for 2021 q3
SEC form 6
2021-09-29 17:07 ET
Coherus Biosciences published news for 2021 q2
SEC form 6
2021-08-11 16:04 ET
Coherus Biosciences published news for 2021 q2
SEC form 10
2021-08-05 16:19 ET
Coherus Biosciences published news for 2021 q2
SEC form 6
2021-08-05 16:06 ET
Coherus Biosciences published news for 2021 q2
SEC form 8
2021-08-05 00:00 ET
Coherus Biosciences published news for 2021 q2
SEC form 10
2021-08-05 00:00 ET
Coherus Biosciences published news for 2021 q2
SEC form 6
2021-05-26 06:05 ET
Coherus Biosciences published news for 2021 q1
SEC form 10
2021-05-06 16:31 ET
Coherus Biosciences published news for 2021 q1
SEC form 6
2021-05-06 16:24 ET
Coherus Biosciences published news for 2021 q1
SEC form 10
2021-05-06 00:00 ET
Coherus Biosciences published news for 2021 q1
SEC form 8
2021-05-06 00:00 ET
Coherus Biosciences published news for 2021 q1
SEC form 6
2021-04-09 16:05 ET
Coherus Biosciences published news for 2021 q1
SEC form 6
2021-03-16 18:10 ET
Coherus Biosciences published news for 2020 q4
SEC form 10
2021-02-25 16:18 ET
Coherus Biosciences published news for 2020 q4
SEC form 6
2021-02-24 16:05 ET
Coherus Biosciences published news for 2020 q4
SEC form 6
2021-02-12 16:41 ET
Coherus Biosciences published news for 2020 q4
SEC form 6
2021-02-02 08:45 ET
Coherus Biosciences published news for 2020 q4
SEC form 6
2021-01-07 16:32 ET
Coherus Biosciences published news for 2020 q4
SEC form 6
2021-01-07 16:30 ET
Coherus Biosciences published news for 2020 q4
SEC form 6
2021-01-07 16:15 ET
Coherus Biosciences published news for 2020 q4
SEC form 6
2020-11-18 16:06 ET
Coherus Biosciences published news for 2020 q3
SEC form 10
2020-11-05 16:17 ET
Coherus Biosciences published news for 2020 q3
SEC form 6
2020-11-05 16:07 ET
Coherus Biosciences published news for 2020 q3